Everpure heads into mid-June with an interesting internal tension: the stock has recovered 4.7% on the week to $73.26, yet its founder has been selling into that strength, and most analysts still see meaningful upside from current levels.
The most notable data point this week is founder activity. John Colgrove — who still holds roughly 3.7% of the company — sold just over 100,000 shares across four transactions on June 12, raising approximately $7.1 million at prices between $70.08 and $71.54. The trades carry a low significance score, which is consistent with a pre-planned disposal programme rather than a discretionary decision, but the timing — right after the stock bounced off its month-long lows — is worth registering. Over the past 90 days, insiders are net buyers in aggregate (roughly $42 million net across the register), so the Colgrove sales read more as routine harvesting than a directional signal against the company.
Short positioning offers no meaningful counter-narrative here. Short interest is running at just under 3% of the free float — and falling, down more than 6% on the week and 14% over the past month. Borrowing costs are negligible at 0.45%, barely changed in any meaningful direction, and borrow availability is extraordinarily loose: over 4,700% of outstanding short interest sits available to lend, well above any level that would flag squeeze pressure. Options positioning is equally neutral, with the put/call ratio at 0.48 — almost precisely at its 20-day average of 0.48 — carrying a z-score of essentially zero. There is no directional conviction embedded in either the short or the derivatives market.
The more interesting story is the gap between where analysts think this stock goes and where it currently trades. Following Q1 results in late May, the bulk of the Street raised targets: JP Morgan lifted its Overweight target from $80 to $92, Wells Fargo moved to $97 on an Overweight, and Guggenheim pushed to $115 on a Buy. Even the lone dissenter — UBS, which holds a Sell — nudged its target up from $63 to $70. The mean target across the covering group now sits near $94, roughly 28% above the current price. Against that, the bear case centres on gross margin pressure from commodity costs, lower free cash flow from elevated commission payments, and uncertainty around whether hyperscaler revenues materialise as forecast. The EV/EBITDA multiple, currently around 20.6x, has compressed about 1.4 turns over the past month, which partially explains the disconnect between analyst enthusiasm and the stock's 10% slide over the past four weeks. One wrinkle: Citigroup downgraded the stock to Neutral from Buy back in mid-May; that move is now about a month old but remains the last rating-change in the bearish direction.
Among the closest US-listed peers, the week has been mixed. NTAP slipped 2.3% while DELL added 5.8%, and WDC surged more than 31% — the kind of divergence that suggests sector-wide tailwinds are not uniformly at work, and that stock-specific drivers are dominating. P's 4.7% weekly gain places it comfortably between those extremes, consistent with a stock where short sellers are retreating but no new catalyst has yet arrived to close the gap to analyst targets.
The next formal catalyst is the August 26 earnings print. Between now and then, the primary variables to watch are whether the founder's selling programme accelerates, whether any analyst who raised targets in May revises guidance expectations, and whether margin commentary at peer results narrows or widens the ongoing debate between a stretched valuation and an improving revenue trajectory.
See the live data behind this article on ORTEX.
Open P on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
